Kappa Bioscience


Vitamin K2 – a crucial ingredient for those growing years

Please click here to activate the video. After activation, data will be transmitted to the respective provider and you agree to our privacy policy.

Children – Applications

See what CEO Egil Greve from Kappa Bioscience has to say about K2.

Play video

By clicking "Continue", data will be transmitted to the respective provider and you agree to our privacy policy.

K2VITAL® supplementation could improve bone quality in children and adolescents

Healthy children can, in fact, suffer from a vitamin K deficiency to the great disadvantage of their current and future bone health. Such children might benefit from K2 supplementation. There is evidence that teenagers have inadequate levels of osteocalcin activation and could benefit from K2VITAL® supplementation. By consuming more K2 MK-7 via supplementation, adolescents can increase the incorporation of calcium into their bones and improve bone quality. It is important that they get K2 MK-7 specifically, in comparison to the more widely available vitamin K1 (such as in most multivitamins) because studies show that MK-7 gives the body a much stronger vitamin K boost compared to a similar amount of K1, and K2 also specifically targets osteocalcin activation.

Human growth peaks during adolescence and this growth spurt coincides with a period of rapid bone development

Vitamin K2 is crucial for bone development from conception to senior years. Bone development begins as early as six weeks after conception and continues into adulthood. Peak bone mass (bone mineral density) is achieved somewhere around the age of 20, then it begins a natural and steady decline. Teens acquire approximately a quarter of their peak bone mass in a period of about two years during adolescence. This peak bone mass sets the stage for bone health throughout the remainder of life. It provides the baseline from which the natural and predictable decline (aging) in bone density will start. A high peak bone mass before age 20 will carry through to better bone health as an adult, with studies demonstrating 50% reduction in risk of certain fractures based on only a 10% difference in adolescent peak bone mass.

Adolescents are likely to be K2 deficient and vitamin K2 supplementation might be necessary to build long-term bone health

Adults need a lot of vitamin K2, at least 90 to 120 μg per day, to maintain the bone mass built up during childhood and early adulthood. Childhood and adolescence are also no exceptions to the requirements of vitamin K2. Childhood is a period of intense skeletal bone growth. The K2 demand for growing adolescents is probably even higher because this period of rapid bone growth requires


higher concentrations of nutrients. Relative to their body weight, teenagers probably need much more K2 compared to adults, and it follows that many adolescents are likely to be K2 deficient absent supplementation. Vitamin K2 MK-7 is particularly important in these early years as K2 helps incorporate calcium into bones by activating osteocalcin. In many cases, K2 deficiencies can go unnoticed.

Recommended daily dosages of vitamin K2 for children have not yet been determined. The National Institute of Medicine of the US National Academy of Sciences recommends minimum daily intakes of vitamin K for infants and children of different ages. The values are based on breastmilk vitamin K contents and intakes (for infants aged 0-12 months) and on data from a major US health and nutrition survey (children/adolescents aged 1-18 years). The recommended intakes for infants and children are the same for males and females.

  • Commercial
  • Quality & Safety
  • Product development
  • Science Papers
  • Applications
  • Experience Cards

Scalable capacity for mass-market production demands: Kappa’s current production capacity already exceeds the total projected yearly global vitamin K2 demand through 2020.
Industry-leading pricing: Kappa continuously reinvests in R&D and manufacturing processes to drive ingredient price points to levels that support commercial adoption. In 2017, Kappa led the market with a 45% price reduction – marking a significant step on the path to mass-market commercialization of K2.

Purity: all-trans vitamin K2 MK-7 (USP).
Quality: GMP, HACCP, ISO 22000:2005 manufacturing and distribution standards.
Stability: Patent-pending microencapsulation technology ensures stability in challenging formulations.
Long shelf life in finished products: 36 months shelf life on all ingredients; supported by extensive stability data on ingredients and finished formulations.
Approvals: Novel Food (EU), TGA (AUS), sGRAS (USA), drug registration in India (2017). Application processes are initiated in countries including China, Thailand and others. Kosher and Halal certifications.

Kappa developed the K2 Formulation LookBook, including more than 120 ready-to-use product formulations and dosage forms targeted towards all K2 health applications and a wide range of consumer groups.

Kappa’s on-going ExperienceCard Program develops innovative vitamin K2 formulations in collaboration with industry leaders. Each ExperienceCard concept represents a novel product formulation that is specifically designed to solve an existing market problem or to address a health segment or consumer group in a new way. K2VITAL® vitamin K2 MK-7 provides the central ingredient in each of the products. Partners provided synergistic co-ingredients, innovative dosage or manufacturing technology, or other elements that make these forward-looking products possible.

Bone Health

More information

Heart Health

More information

Customer Download Portal

Sign up | Reset password

Sales and Marketing
Kappa Ingredients GmbH
Friesenweg 4 | Building 13 | 22763 Hamburg

Kappa Bioscience AS
Silurveien 2 | Building B | 0380 Oslo

+49 40 6094087 0
Sales team USA: +1 609 201 1459